1. Effect of evolocumab on lipoprotein particles
Mean % change from baseline to week 52 (95%CI)
Total LDL-p
Total HDL-p
Total VLDL-p/ chylomicron
IDL-p
Evolocumab
(N=294)
-44.1 (-47.2 to -40.9)
9.4 ( )
(-39.3 to 15.4)
-36.2 (-69.8 to 22.0)
Placebo
(N=236)
6.4 (2.9 – 9,9)
-0.1 (-1.6 to 1.4)
-0.3 (-26.3 to 31.7)
0 (-47.4 to 87.5)
P value
P <0.0001
P <0.001
CI: confidence interval; QM: once every month; LDL-p: low-density lipoprotein particle concentration; HDL-p: high-density lipoprotein particle concentration; VLDL-p: very low-density lipoprotein particle concentration; IDL-p: intermediate-density lipoprotein particle concentration;
Toth PP, et al. Am J Cardiol 2018;121:308–314